Skip to main content

Articles

Page 1 of 39

  1. Oncolytic viruses (OVs) offer a novel approach to treat solid tumors; however, their efficacy is frequently suboptimal due to various limiting factors. To address this challenge, we engineered an OV containing...

    Authors: Yiye Zhong, Huangying Le, Xue Zhang, Yao Dai, Fang Guo, Xiaojuan Ran, Guohong Hu, Qi Xie, Dawei Wang and Yujia Cai
    Citation: Journal of Hematology & Oncology 2024 17:36
  2. Angiosarcoma is a rare subtype of malignant neoplasm originating from vascular or lymphatic endothelial cells; its low incidence has posed significant challenges for comprehensive investigations into its patho...

    Authors: Da Jung Jung, Jae Hee Byeon, Young Chul Kim, Woo Shik Jeong, Jong-Woo Choi and Gi Seok Jeong
    Citation: Journal of Hematology & Oncology 2024 17:35
  3. Disseminated adenovirus infection is a complication with a relatively high mortality rate among patients undergoing hematopoietic stem cell transplantation. The low efficacy and poor availability of current tr...

    Authors: Fei Zhou, Feng Du, Ziyan Wang, Mengxing Xue, Depei Wu, Suning Chen and Xuefeng He
    Citation: Journal of Hematology & Oncology 2024 17:34
  4. The gut microbiota plays a critical role in the progression of human diseases, especially cancer. In recent decades, there has been accumulating evidence of the connections between the gut microbiota and cance...

    Authors: Zehua Li, Weixi Xiong, Zhu Liang, Jinyu Wang, Ziyi Zeng, Damian Kołat, Xi Li, Dong Zhou, Xuewen Xu and Linyong Zhao
    Citation: Journal of Hematology & Oncology 2024 17:33
  5. Inotuzumab ozogamicin (INO) is an anti-CD22 antibody-drug conjugate that was first evaluated in B-cell lymphomas but was subsequently shown to be highly effective in acute lymphoblastic leukemia (ALL). INO imp...

    Authors: Nicholas J. Short, Elias Jabbour, Nitin Jain and Hagop Kantarjian
    Citation: Journal of Hematology & Oncology 2024 17:32
  6. Glioblastoma (GBM), the predominant and primary malignant intracranial tumor, poses a formidable challenge due to its immunosuppressive microenvironment, thereby confounding conventional therapeutic interventi...

    Authors: Hao Lin, Chaxian Liu, Ankang Hu, Duanwu Zhang, Hui Yang and Ying Mao
    Citation: Journal of Hematology & Oncology 2024 17:31
  7. As the most common form of epigenetic regulation by RNA, N6 methyladenosine (m6A) modification is closely involved in physiological processes, such as growth and development, stem cell renewal and differentiation...

    Authors: Guotai Feng, Yongya Wu, Yuan Hu, Wen Shuai, Xiao Yang, Yong Li, Liang Ouyang and Guan Wang
    Citation: Journal of Hematology & Oncology 2024 17:30
  8. Currently, many off-the-shelf chimeric antigen receptor (CAR)-T cell products are under investigation for the treatment of relapsed or refractory (R/R) B-cell neoplasms. Compared with autologous CAR-T cell the...

    Authors: Yun Kang, Chenggong Li and Heng Mei
    Citation: Journal of Hematology & Oncology 2024 17:29
  9. Patients with cytogenetically normal acute myeloid leukemia (CN-AML) may harbor prognostically relevant gene mutations and thus be categorized into one of the three 2022 European LeukemiaNet (ELN) genetic-risk...

    Authors: Kellie J. Archer, Han Fu, Krzysztof Mrózek, Deedra Nicolet, Alice S. Mims, Geoffrey L. Uy, Wendy Stock, John C. Byrd, Wolfgang Hiddemann, Jan Braess, Karsten Spiekermann, Klaus H. Metzeler, Tobias Herold and Ann-Kathrin Eisfeld
    Citation: Journal of Hematology & Oncology 2024 17:28
  10. The rapid advancements in large language models (LLMs) such as ChatGPT have raised concerns about their potential impact on academic integrity. While initial concerns focused on ChatGPT’s writing capabilities,...

    Authors: Lingxuan Zhu, Yancheng Lai, Weiming Mou, Haoran Zhang, Anqi Lin, Chang Qi, Tao Yang, Liling Xu, Jian Zhang and Peng Luo
    Citation: Journal of Hematology & Oncology 2024 17:27
  11. Constitutional heterozygous pathogenic variants in genes coding for some components of the Fanconi anemia-BRCA signaling pathway, which repairs DNA interstrand crosslinks, represent risk factors for common can...

    Authors: Svenja Kastellan, Reinhard Kalb, Bia Sajjad, Lisa J. McReynolds, Neelam Giri, David Samuel, Till Milde, Miriam Elbracht, Susanne Holzhauer, Marena R. Niewisch and Christian P. Kratz
    Citation: Journal of Hematology & Oncology 2024 17:26
  12. Hepatocellular carcinoma (HCC) is a major health concern worldwide, with limited therapeutic options and poor prognosis. In recent years, immunotherapies such as immune checkpoint inhibitors (ICIs) have made g...

    Authors: Ke-Yu Shen, Ying Zhu, Sun-Zhe Xie and Lun-Xiu Qin
    Citation: Journal of Hematology & Oncology 2024 17:25
  13. Although killer Ig-like receptor ligands (KIR-L) mismatch has been associated with alloreactive natural killer cell activity and potent graft-versus-leukemia (GVL) effect among adults with acute myeloid leukem...

    Authors: Hisashi Ishida, Yuta Kawahara, Daisuke Tomizawa, Yasuhiro Okamoto, Asahito Hama, Yuko Cho, Katsuyoshi Koh, Yuhki Koga, Nao Yoshida, Maho Sato, Kiminori Terui, Naoyuki Miyagawa, Akihiro Watanabe, Junko Takita, Ryoji Kobayashi, Masaki Yamamoto…
    Citation: Journal of Hematology & Oncology 2024 17:24
  14. The autologous anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy LCAR-B38M has been approved for the treatment of relapsed and refractory multiple myeloma in many countries a...

    Authors: Jie Xu, Bai-Yan Wang, Shan-He Yu, Shi-Jun Chen, Shuang-Shuang Yang, Rui Liu, Li-Juan Chen, Jian Hou, Zhu Chen, Wan-Hong Zhao, Ai-Li He, Jian-Qing Mi and Sai-Juan Chen
    Citation: Journal of Hematology & Oncology 2024 17:23
  15. Tumor is a local tissue hyperplasia resulted from cancerous transformation of normal cells under the action of various physical, chemical and biological factors. The exploration of tumorigenesis mechanism is c...

    Authors: Shimeng Zhou, Junlan Liu, Andi Wan, Yi Zhang and Xiaowei Qi
    Citation: Journal of Hematology & Oncology 2024 17:22
  16. Relapse and toxicity limit the effectiveness of chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphoma (LBCL), yet biomarkers that predict outcomes and toxicity are lacking. We examined rad...

    Authors: Doris Leithner, Jessica R. Flynn, Sean M. Devlin, Audrey Mauguen, Teng Fei, Shang Zeng, Junting Zheng, Brandon S. Imber, Harper Hubbeling, Marius E. Mayerhoefer, Akshay Bedmutha, Efrat Luttwak, Magdalena Corona, Parastoo B. Dahi, Alejandro Luna de Abia, Ivan Landego…
    Citation: Journal of Hematology & Oncology 2024 17:21
  17. EGFR and/or HER2 expression in pancreatic cancers is correlated with poor prognoses. We generated homodimeric (EGFRxEGFR or HER2xHER2) and heterodimeric (EGFRxHER2) T cell-engaging bispecific antibodies (T-BsA...

    Authors: Alan W Long, Hong Xu, Brian H Santich, Hongfen Guo, Sayed Shahabuddin Hoseini, Elisa de Stanchina and Nai-Kong V Cheung
    Citation: Journal of Hematology & Oncology 2024 17:20
  18. Bendamustine has been retrospectively shown to be an effective and safe lymphodepletion regimen prior to the anti-CD19 chimeric antigen receptor T cell (CART) products tisagenlecleucel and axicabtagene ciloleu...

    Authors: Guido Ghilardi, Luca Paruzzo, Vrutti Patel, Jakub Svoboda, Emeline R. Chong, Eugenio Fardella, Elise A. Chong, Giulia Gabrielli, Sunita D. Nasta, Daniel J. Landsburg, Jordan Carter, Raymone Pajarillo, Stefan K. Barta, Griffin White, Elizabeth Weber, Ellen Napier…
    Citation: Journal of Hematology & Oncology 2024 17:19
  19. The chemo-free concept represents a new direction for managing adult patients with Ph-positive acute lymphoblastic leukemia (Ph + ALL). The tyrosine kinase inhibitors (TKIs), blinatumomab and venetoclax serve ...

    Authors: Ting Shi and Hong-Hu Zhu
    Citation: Journal of Hematology & Oncology 2024 17:18
  20. Evidence from Europe shows that perioperative chemotherapy may be beneficial for the treatment of locally advanced gastric cancer, but reliable and robust data is lacking. To rectify this, the phase 3 RESONANC...

    Authors: Xinxin Wang, Canrong Lu, Bo Wei, Shuo Li, Ziyu Li, Yingwei Xue, Yingjiang Ye, Zhongtao Zhang, Yihong Sun, Han Liang, Kai Li, Linghua Zhu, Zhichao Zheng, Yanbing Zhou, Yulong He, Fei Li…
    Citation: Journal of Hematology & Oncology 2024 17:17
  21. Cancer immunotherapy and vaccine development have significantly improved the fight against cancers. Despite these advancements, challenges remain, particularly in the clinical delivery of immunomodulatory comp...

    Authors: Qiang Lu, Dongquan Kou, Shenghan Lou, Milad Ashrafizadeh, Amir Reza Aref, Israel Canadas, Yu Tian, Xiaojia Niu, Yuzhuo Wang, Pedram Torabian, Lingzhi Wang, Gautam Sethi, Vinay Tergaonkar, Franklin Tay, Zhennan Yuan and Peng Han
    Citation: Journal of Hematology & Oncology 2024 17:16
  22. The T-cell receptor (TCR) repertoires exhibits distinct signatures associated with COVID-19 severity. However, the precise identification of vaccine-induced SARS-CoV-2-specific TCRs and T-cell immunity mechani...

    Authors: Qian Zhang, Qing Liang, Rui Zhang, Nan Wang, Xu Xiao, Jiahao Shao and Kejia Wang
    Citation: Journal of Hematology & Oncology 2024 17:15
  23. Protein degraders, emerging as a novel class of therapeutic agents, have gained widespread attention due to their advantages. They have several advantages over traditional small molecule inhibitors, including ...

    Authors: Guangcai Zhong, Ran Kong, Shi Feng, Cong Wang, Qingbo Hao, Weilin Xie and Xiangxiang Zhou
    Citation: Journal of Hematology & Oncology 2024 17:14
  24. Inflammation has accompanied human beings since the emergence of wounds and infections. In the past decades, numerous efforts have been undertaken to explore the potential role of inflammation in cancer, from ...

    Authors: Manni Wang, Siyuan Chen, Xuemei He, Yong Yuan and Xiawei Wei
    Citation: Journal of Hematology & Oncology 2024 17:13
  25. Cancer early detection and treatment response prediction continue to pose significant challenges. Cancer liquid biopsies focusing on detecting circulating tumor cells (CTCs) and DNA (ctDNA) have shown enormous...

    Authors: Kai He, Maryam Baniasad, Hyunwoo Kwon, Tomislav Caval, Gege Xu, Carlito Lebrilla, Daniel W. Hommes and Carolyn Bertozzi
    Citation: Journal of Hematology & Oncology 2024 17:12
  26. Immunotherapy is the first-line therapy for esophageal squamous cell carcinoma (ESCC), yet many patients do not respond due to drug resistance and the lack of reliable predictive markers. We collected 73 ESCC ...

    Authors: Fahan Ma, Yan Li, Chan Xiang, Bing Wang, Jie Lv, Jinzhi Wei, Zhaoyu Qin, Yan Pu, Kai Li, Haohua Teng, Subei Tan, Jinwen Feng, Zhanxian Shang, Yunzhi Wang, Sha Tian, Changsheng Du…
    Citation: Journal of Hematology & Oncology 2024 17:11
  27. Liquid biopsy, which is a minimally invasive procedure as an alternative to tissue biopsy, has been introduced as a new diagnostic/prognostic measure. By screening disease-related markers from the blood or oth...

    Authors: Young Jun Kim, Won-Yeop Rho, Seung-min Park and Bong-Hyun Jun
    Citation: Journal of Hematology & Oncology 2024 17:10
  28. Emerging evidences suggest that aberrant metabolites contributes to the immunosuppressive microenvironment that leads to cancer immune evasion. Among tumor immunosuppressive cells, myeloid-derived suppressor c...

    Authors: Zeda Zhao, Juliang Qin, Ying Qian, Chenshen Huang, Xiaohong Liu, Ning Wang, Liqin Li, Yuqing Chao, Binghe Tan, Na Zhang, Min Qian, Dali Li, Mingyao Liu and Bing Du
    Citation: Journal of Hematology & Oncology 2024 17:9
  29. It remains challenging to obtain positive outcomes with chimeric antigen receptor (CAR)-engineered cell therapies in solid malignancies, like colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC)...

    Authors: Astrid Van den Eynde, Laura Gehrcken, Tias Verhezen, Ho Wa Lau, Christophe Hermans, Hilde Lambrechts, Tal Flieswasser, Delphine Quatannens, Gils Roex, Karen Zwaenepoel, Elly Marcq, Philippe Joye, Edgar Cardenas De La Hoz, Christophe Deben, Alessia Gasparini, Pierre Montay-Gruel…
    Citation: Journal of Hematology & Oncology 2024 17:8
  30. While liver cancer stem cells (CSCs) play a crucial role in hepatocellular carcinoma (HCC) initiation, progression, recurrence, and treatment resistance, the mechanism underlying liver CSC self-renewal remains...

    Authors: Meilin Xue, Lei Dong, Honghai Zhang, Yangchan Li, Kangqiang Qiu, Zhicong Zhao, Min Gao, Li Han, Anthony K. N. Chan, Wei Li, Keith Leung, Kitty Wang, Sheela Pangeni Pokharel, Ying Qing, Wei Liu, Xueer Wang…
    Citation: Journal of Hematology & Oncology 2024 17:7
  31. Cancer is a complex disease resulting from abnormal cell growth that is induced by a number of genetic and environmental factors. The tumor microenvironment (TME), which involves extracellular matrix, cancer-a...

    Authors: Hongying Zhang, Yongliang Liu, Jieya Liu, Jinzhu Chen, Jiao Wang, Hui Hua and Yangfu Jiang
    Citation: Journal of Hematology & Oncology 2024 17:5
  32. Myelodysplastic neoplasms (MDS) define clonal hematopoietic malignancies characterized by heterogeneous mutational and clinical spectra typically seen in the elderly. Curative treatment entails allogeneic hema...

    Authors: Kriti Gera, Anjali Chauhan, Paul Castillo, Maryam Rahman, Akash Mathavan, Akshay Mathavan, Elizabeth Oganda-Rivas, Leighton Elliott, John R. Wingard and Elias J. Sayour
    Citation: Journal of Hematology & Oncology 2024 17:4
  33. Herbicide and pesticide exposure [e.g., agent orange (AO)] is associated with an increased risk of multiple myeloma (MM) due to the contaminant, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). However, it is unclear ...

    Authors: Lawrence W. Liu, Mei Wang, Nikhil Grandhi, Mark A. Schroeder, Theodore Thomas, Kristin Vargo, Feng Gao, Kristen M. Sanfilippo and Su-Hsin Chang
    Citation: Journal of Hematology & Oncology 2024 17:3
  34. The use of peripheral blood (PB) or bone marrow (BM) stem cells graft in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD)...

    Authors: Claire Lacan, Jérôme Lambert, Edouard Forcade, Marie Robin, Patrice Chevallier, Sandrine Loron, Claude-Éric Bulabois, Corentin Orvain, Patrice Ceballos, Etienne Daguindau, Amandine Charbonnier, Yves Chalandon, Marc Bernard, Célestine Simand, Marie-Thérèse Rubio, Pascal Turlure…
    Citation: Journal of Hematology & Oncology 2024 17:2
  35. Antibody-drug conjugates (ADCs) represent an important class of cancer therapies that have revolutionized the treatment paradigm of solid tumors. To date, many ongoing studies of ADC combinations with a variet...

    Authors: Qing Wei, Peijing Li, Teng Yang, Jiayu Zhu, Lu Sun, Ziwen Zhang, Lu Wang, Xuefei Tian, Jiahui Chen, Can Hu, Junli Xue, Letao Ma, Takaya Shimura, Jianmin Fang, Jieer Ying, Peng Guo…
    Citation: Journal of Hematology & Oncology 2024 17:1
  36. Patients with mantle cell lymphoma (MCL) exhibit a wide variation in clinical presentation and outcome. However, the commonly used prognostic models are outdated and inadequate to address the needs of the curr...

    Authors: Julie M. Vose, Kai Fu, Lu Wang, Adnan Mansoor, Douglas Stewart, Hongxia Cheng, Lynette Smith, Ji Yuan, Hina Naushad Qureishi, Brian K. Link, Melissa H. Cessna, Paul M. Barr, Brad S. Kahl, Matthew S. Mckinney, Nadia Khan, Ranjana H. Advani…
    Citation: Journal of Hematology & Oncology 2023 16:122
  37. Brain metastases signify a deleterious milestone in the progression of several advanced cancers, predominantly originating from lung, breast and melanoma malignancies, with a median survival timeframe nearing ...

    Authors: Dairan Zhou, Zhenyu Gong, Dejun Wu, Chao Ma, Lijun Hou, Xiaomin Niu and Tao Xu
    Citation: Journal of Hematology & Oncology 2023 16:121
  38. Global proteomic data generated by advanced mass spectrometry (MS) technologies can help bridge the gap between genome/transcriptome and functions and hold great potential in elucidating unbiased functional mo...

    Authors: Won-Min Song, Abdulkadir Elmas, Richard Farias, Peng Xu, Xianxiao Zhou, Benjamin Hopkins, Kuan-lin Huang and Bin Zhang
    Citation: Journal of Hematology & Oncology 2023 16:120
  39. In retrospective studies, metformin use has been associated with better clinical outcomes in diabetic patients with advanced, well-differentiated neuroendocrine tumors (WDNETs). However, prospective evidence o...

    Authors: Sara Pusceddu, Francesca Corti, Natalie Prinzi, Federico Nichetti, Silva Ljevar, Adele Busico, Tommaso Cascella, Rita Leporati, Simone Oldani, Chiara Carlotta Pircher, Jorgelina Coppa, Veronica Resi, Massimo Milione, Marco Maccauro, Rosalba Miceli, Elena Tamborini…
    Citation: Journal of Hematology & Oncology 2023 16:119
  40. Antibody–drug conjugates (ADCs) have emerged as a novel therapeutic strategy that has successfully reached patient treatment in different clinical scenarios. ADCs are formed by an antibody against a specific t...

    Authors: Alfonso López de Sá, Cristina Díaz-Tejeiro, Elisa Poyatos-Racionero, Cristina Nieto-Jiménez, Lucía Paniagua-Herranz, Adrián Sanvicente, Emiliano Calvo, Pedro Pérez-Segura, Víctor Moreno, Francisco Moris and Alberto Ocana
    Citation: Journal of Hematology & Oncology 2023 16:118
  41. T-cell retargeting to eliminate CEACAM5-expressing cancer cells via CEACAM5xCD3 bispecific antibodies (BsAbs) showed limited clinical activity so far, mostly due to insufficient T-cell activation, dose-limitin...

    Authors: Anja Seckinger, Sara Majocchi, Valéry Moine, Lise Nouveau, Hoang Ngoc, Bruno Daubeuf, Ulla Ravn, Nicolas Pleche, Sebastien Calloud, Lucile Broyer, Laura Cons, Adeline Lesnier, Laurence Chatel, Anne Papaioannou, Susana Salgado-Pires, Sebastian Krämer…
    Citation: Journal of Hematology & Oncology 2023 16:117
  42. Inflammation is a fundamental defensive response to harmful stimuli, but the overactivation of inflammatory responses is associated with most human diseases. Reactive oxygen species (ROS) are a class of chemic...

    Authors: Jiatong Liu, Xiaoyue Han, Tingyue Zhang, Keyue Tian, Zhaoping Li and Feng Luo
    Citation: Journal of Hematology & Oncology 2023 16:116
  43. T cell engagers (TCEs) have been established as an emerging modality for hematologic malignancies, but solid tumors remain refractory. However, the upregulation of programmed cell death 1 (PD-1) is correlated ...

    Authors: Ziqiang Ding, Shuyang Sun, Xuan Wang, Xiaomei Yang, Wei Shi, Xianing Huang, Shenxia Xie, Fengzhen Mo, Xiaoqiong Hou, Aiqun Liu, Xiaobing Jiang, Zhuoran Tang and Xiaoling Lu
    Citation: Journal of Hematology & Oncology 2023 16:115
  44. Research into the potential benefits of artificial intelligence for comprehending the intricate biology of cancer has grown as a result of the widespread use of deep learning and machine learning in the health...

    Authors: Chaoyi Zhang, Jin Xu, Rong Tang, Jianhui Yang, Wei Wang, Xianjun Yu and Si Shi
    Citation: Journal of Hematology & Oncology 2023 16:114
  45. T-cell acute lymphoblastic leukemia (T-ALL) is a type of hematologic tumor with malignant proliferation of hematopoietic progenitor cells. However, traditional clinical treatment of T-ALL included chemotherapy...

    Authors: Long Chen, Anqi Ren, Yuan Zhao, Hangyu Chen, Qifang Wu, Mengzhu Zheng, Zijian Zhang, Tongcun Zhang, Wu Zhong, Jian Lin and Haichuan Zhu
    Citation: Journal of Hematology & Oncology 2023 16:113
  46. Significant scientific advances in immunotherapy and targeted therapy approaches have improved clinical outcomes and increased treatment options for patients with genitourinary (GU) malignancies. We highlight ...

    Authors: Qian Qin, Hollie Sheffield, Sean M. Taasan, Andrew Z. Wang and Tian Zhang
    Citation: Journal of Hematology & Oncology 2023 16:112
  47. Chimeric antigen receptor T-cell therapy (CAR-T) has been successful in treating relapsed/refractory B-cell lymphomas. However, its role in the treatment of diseases involving the central nervous system (CNS) ...

    Authors: Narendranath Epperla, Lei Feng, Nirav N. Shah, Lindsey Fitzgerald, Harsh Shah, Deborah M. Stephens, Catherine J. Lee, Thomas Ollila, Geoffrey Shouse, Alexey V. Danilov, Kevin A. David, Pallawi Torka, Hamza Hashmi, Brian Hess, Stefan K. Barta, Jason T. Romancik…
    Citation: Journal of Hematology & Oncology 2023 16:111
  48. Authors: Qian Zhu, Ai-Lin Zhong, Hao Hu, Jing-Jing Zhao, De-Sheng Weng, Yan Tang, Qiu-Zhong Pan, Zi-Qi Zhou, Meng-Jia Song, Jie-Ying Yang, Jun-Yi He, Yuan Liu, Min Li, Wan-Ming Hu, Chao-Pin Yang, Tong Xiang…
    Citation: Journal of Hematology & Oncology 2023 16:110

    The original article was published in Journal of Hematology & Oncology 2020 13:2

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here